Podcasts about GIP

Precise receptor mapping is reshaping how we understand incretin biology. David Hodson explains how GPCR-targeted chemical probes reveal where GLP-1 and GIP receptors actually signal across pancreas and brain—and what this means for metabolic drug design.Learn how these tools refine gpcr drug discovery, clarify receptor internalization, and guide next-gen therapeutics.

Welcome to Ozempic Weightloss Unlocked, where we decode the latest breakthroughs, news, and hidden truths about one of the world's most talked-about weight loss drugs. Today, the buzz is about change—how new research, fresh delivery methods, and evolving regulations are reshaping the Ozempic story. Let us start with what is most recent. There is a big development: needles may no longer be necessary. According to reporting in Popular Mechanics and new data published in The New England Journal of Medicine, Novo Nordisk, the maker of Ozempic and Wegovy, has released results for a daily oral version of semaglutide, the active ingredient in Ozempic. In their clinical trial, this pill matched the weight loss produced by the weekly injection, with an average of 16.6 percent reduction in body weight. About a third of participants lost more than 20 percent. While side effects like nausea and vomiting were reported at higher rates than placebo, this new pill could make using these drugs more accessible than ever.Access is also the hot topic in pricing. Until this year, monthly Ozempic prescriptions could cost up to $1,350 without insurance support. But after new negotiations, many users will soon pay $50 to $350 per month, depending on dosage and coverage. Lower prices are expected to make these drugs far more widely available.So, how well does Ozempic stack up in its primary role? Ozempic was first approved to treat type two diabetes, with weight loss as a major secondary effect. Harper Clinic Utah reports that, in clinical trials, people using Ozempic lost on average between 10 and 15 percent of their body weight over a little more than a year. But real world success depends on how consistently people use it and whether they also improve their diet and exercise habits.Now a common question—how does Ozempic compare to newer weight loss options like Zepbound and Wegovy? The main distinction is the active ingredient. Ozempic uses semaglutide, which triggers the body to release the hormone GLP-1, helping you feel fuller and slow digestion. Zepbound uses tirzepatide, which mimics both GLP-1 and a second hormone called GIP, and results from major trials suggest it can lead to more dramatic weight loss—up to 21 percent of body weight in some studies. However, Ozempic remains covered by insurance for diabetes, while Zepbound is less often covered.Beyond weight, a new area of research is exploring how Ozempic could affect long-term health conditions. According to ScienceDaily, a recent large-scale analysis found that when people stop using prescription weight loss drugs like Ozempic, they tend to regain much of their lost weight, underscoring the need for ongoing treatment or lifestyle change. But these medicines may do much more than affect weight. Recent studies at University of California San Diego found that people with colon cancer who were on GLP-1 drugs were less than half as likely to die within five years. Another new UVA study, covered by Fox News and ScienceDaily, points to dramatically lower death rates in cancer patients who use GLP-1 drugs like Ozempic—potentially because they lower inflammation and improve metabolic health.There is also new investigation about Ozempic's possible use in treating long COVID. According to research covered by ClickOnDetroit, anecdotal reports suggest that some people taking GLP-1 drugs for weight loss also experienced improvement in their post-COVID symptoms, and new clinical trials are underway.Despite these major advances, affordability and access remain challenges. The latest KFF Health Tracking Poll says that about one in eight adults in the United States are now taking a GLP-1 medication like Ozempic, Wegovy, or Zepbound. But half of those surveyed still find the drugs financially out of reach, even as prices are starting to come down.What does all this mean for lifestyle and health? The current scientific consensus is clear: these drugs do not replace needed changes in eating habits and physical activity. As physicians emphasize, Ozempic works best as part of a treatment plan that includes real lifestyle change.As you can see, Ozempic and drugs like it are not just a story about slimming down—they are opening doors to better health, new medical research, and greater access for millions. Thank you for tuning in to Ozempic Weightloss Unlocked. Make sure to subscribe so you do not miss the next episode covering the evolving science and your questions about Ozempic and weight loss. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Send us a textChris Broomhead is a bodybuilder, personal trainer and coach, educator, entrepreneur, and advocate for science-backed performance & health. After 14+ years competing in bodybuilding, he is now dedicated to cutting through hype in health and performance.Today, Chris focuses on GLP-1s and peptides, such as Semaglutide, Tirzepatide, Retatrutide, teaching how science and lifestyle work together for resilience, longevity, and transformation.Find Chris at-IG- @Chris_Broomhead_researchYT- @Chris Broomhead CoachingFind Boundless Body at- myboundlessbody.com Book a session with us here!

Solar Dominates 2025 Energy Additions; Nuclear Sees Major Expansion Welcome to our weekly Renewable Energy Briefing! Stay informed on the latest industry trends.  Episode #38 Briefing Highlights: -U.S. government and Westinghouse in $80 billion deal for new nuclear power  -Global Infrastructure Partners (GIP) in a massive deal to acquire utility giant AES  -New federal report shows solar made up almost three-quarters of all new power in 2025 (19GW) -Federal government cancels $7 billion for low-income solar; over 20 states are now suing Solar continues its dominance in 2025, accounting for 19 GW of the 26 GW of new U.S. energy capacity added this year. Meanwhile, the nuclear renaissance accelerates as the U.S. government and Westinghouse announce an $80B deal that reshapes the future of baseload power. Benoy and David break down the biggest transactions—including GIP's acquisition of AES—and the implications of federal policy changes, such as the Trump administration canceling $7B in solar grants aimed at low-income communities. Get the clean energy insights you need in five minutes. Join us for a comprehensive analysis that combines expert commentary with up-to-the-minute news, offering you a strategic overview of the renewable energy market. Don't miss out on the crucial details that can impact your investment decisions. Tune in weekly for your essential dose of Renewable Energy insights! Host Bio: Benoy Thanjan Benoy Thanjan is the Founder and CEO of Reneu Energy, solar developer and consulting firm, and a strategic advisor to multiple cleantech startups. Over his career, Benoy has developed over 100 MWs of solar projects across the U.S., helped launch the first residential solar tax equity funds at Tesla, and brokered $45 million in Renewable Energy Credits (“REC”) transactions.   Prior to founding Reneu Energy, Benoy was the Environmental Commodities Trader in Tesla's Project Finance Group, where he managed one of the largest environmental  commodities portfolios. He originated REC trades and co-developed a monetization and hedging strategy with senior leadership to enter the East Coast market.   As Vice President at Vanguard Energy Partners, Benoy crafted project finance solutions for commercial-scale solar portfolios. His role at Ridgewood Renewable Power, a private equity fund with 125 MWs of U.S. renewable assets, involved evaluating investment opportunities and maximizing returns. He also played a key role in the sale of the firm's renewable portfolio.   Earlier in his career, Benoy worked in Energy Structured Finance at Deloitte & Touche and Financial Advisory Services at Ernst & Young, following an internship on the trading floor at D.E. Shaw & Co., a multi billion dollar hedge fund.   Benoy holds an MBA in Finance from Rutgers University and a BS in Finance and Economics from NYU Stern, where he was an Alumni Scholar. Connect with Benoy on LinkedIn: https://www.linkedin.com/in/benoythanjan/ Learn more: https://reneuenergy.com https://www.solarmaverickpodcast.com     Host Bio: David Magid David Magid is a seasoned renewable energy executive with deep expertise in solar development, financing, and operations. He has worked across the clean energy value chain, leading teams that deliver distributed generation and community solar projects. David is widely recognized for his strategic insights on interconnection, market economics, and policy trends shaping the U.S. solar industry. Connect with David on LinkedIn: https://www.linkedin.com/in/davidmagid/   If you have any questions or comments, you can email us at info@reneuenergy.com.  

Perchè Vincenzo Lanni, l'accoltellatore di piazza Gae Aulenti era libero di circolare nonostante i precedenti di pericolosità? Davanti al Gip che ha convalidato l'arresto ha detto di aver scelto una vittima a caso in un luogo simbolo del potere economico. Ne parliamo con il suo legale. Ci occupiamo poi di una norma di Regione Piemonte ritenuta dal Tribunale di Torino discriminatoria verso gli stranieri perchè prevede per loro l'assegnazione di una casa popolare solo in presenza di un contratto di lavoro. Infine riflettiamo sul caso di Siska, la ragazza di 26 anni belga morta a seguito di eutanasia perchè sofferente di depressione e sindrome post-traumatica.

Show Notes / SummaryWhy launch hospice now: continuity, fewer hospitalizations, value-based alignmentClarifying myths: CNA hours on hospice, attending provider still leads careRAF & staffing logic: ~$6k/mo hospice per diem ↔ RAF ~5; translating RAF → weekly CNA/CHW hoursNurse incentives: $150 per admission; double telehealth-assist credit on hospice patientsSoftware + workflow: Athena ↔ WellSky (care plans, documentation, pull-through)Facility model: converting buildings; estimating FTEs from hospice census + RAFChaplain/social work: leverage in-region LSWs; connect to patient's faith communityRespite options: Medicare respite/GIP + GUIDE program for dementia (up to $2,500yr)Therapy as palliative strength: weekly PTA/COTA; telehealth supportAfter-hours model: optional call, $300 RN death/critical visit; $150 for non-nurse critical checksGuardrails: clinical judgment first; financials inform—not dictate—care www.YourHealth.Org

Today, we're tackling a question that comes up often in peptide, weight loss, and nutrition clinics: why does one person see great results with semaglutide, while another responds better to tirzepatide—or even retatrutide? If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. https://pepties.com/partners/ All three peptides target the incretin system, but they act in slightly different ways—and those differences can dramatically affect outcomes. Let's start with the basics. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics the gut hormone GLP-1, which increases insulin when blood sugar is high (to help lower blood sugar), suppresses glucagon (which also decreases blood sugar), and slows gastric emptying. It also enhances satiety—so you feel full longer and eat less. Tirzepatide is a dual agonist, acting on both GLP-1 and GIP receptors. GIP—glucose-dependent insulinotropic polypeptide—also helps with insulin secretion to lower blood sugar, increases fat metabolism, and may reduce some of the GI side effects seen with GLP-1 alone. Retatrutide, the newest in the lineup, is a triple agonist that targets GLP-1, GIP, and glucagon receptors. Retatrutide lightly activates the glucagon receptor while strongly activating GLP-1 and GIP receptors, which help regulate blood sugar and boost insulin secretion. This keeps blood sugar stable—or even improves it. Beyond blood sugar, glucagon also ramps up metabolism and calorie burning. By gently engaging glucagon receptors, retatrutide can increase energy expenditure and support fat loss without triggering large blood sugar spikes. So how do you decide which one might work best? Let's walk through common clinical situations. Patients with Hypothyroidism Let's talk about hypothyroidism. People with hypothyroidism often have slower metabolism, making weight loss more difficult even with a balanced diet. Low thyroid hormone levels slow calorie burning and energy use, so weight gain can occur more easily. For these patients, semaglutide is a reliable starting point—it helps regulate appetite and caloric intake. If progress plateaus, tirzepatide or retatrutide may provide an edge by boosting energy expenditure and fat oxidation, essentially "jump-starting" a slower metabolism. Patients with PCOS (Polycystic Ovary Syndrome) What about patients with PCOS (polycystic ovary syndrome)? Insulin resistance is common in PCOS, often leading to higher androgen levels (e.g., testosterone) and symptoms like irregular periods, acne, and excess hair growth. Hormonal changes also affect appetite-regulating hormones, increasing hunger and cravings. Both GLP-1 and dual agonists have proven effective in managing metabolic and reproductive aspects of PCOS. Typically, we start with semaglutide to improve weight, insulin sensitivity, androgen levels, and menstrual regularity. After a few months, if weight loss plateaus or cravings remain high, we may switch to tirzepatide. The added GIP activity enhances fat metabolism, insulin control, and may further support hormone regulation and ovulation. The key is starting with what's well-studied and tolerated, then stepping up if additional metabolic or reproductive support is needed. Type 2 Diabetes (T2DM) The next medical condition I'd like to talk about is type 2 diabetes (T2DM). Weight gain in T2DM often stems from insulin resistance. Cells don't respond effectively to insulin, prompting the pancreas to relelase more. High insulin levels encourage fat storage, particularly around the abdomen, while elevated blood sugar can increase hunger and cravings. Some diabetes medications, like insulin or sulfonylureas (e.g., glipizide or glyburide), can also contribute to weight gain. All three drugs lower blood sugar and promote weight loss, but tirzepatide currently shows the strongest combined A1c reduction (average blood sugar over the past 2 to 3 months) and weight loss. GIP and GLP-1 work together to enhance insulin response more effectively than GLP-1 alone. Retatrutide is in phase 3 trials, with potential FDA approval as early as 2027. Its glucagon receptor activity may offer additional glucose regulation and energy expenditure benefits. Patients with >15% Weight Loss Goals Okay, let's talk about weight loss goals and how this ties into the decision process for choosing a weight loss medication. For those patients looking to lose more than 15% of their total body weight, tirzepatide or retatrutide are likely to deliver greater results. Clinical data show semaglutide can achieve up to 15% total weight loss while tirzepatide can achieve up to 22% and retatrutide up to 24%. That said, semaglutide remains a highly effective option for weight loss. However, if progress begins to plateau, transitioning to a dual or triple agonist may help restart weight loss and push past that plateau. Pre- and Postmenopausal Women What about peri- and postmenopausal patients? Hormonal shifts during perimenopause and menopause slow metabolism and can increase cravings. Declining estrogen promotes abdominal fat storage and affects appetite-regulating hormones. Semaglutide helps with appetite control and gradual fat loss, while tirzepatide's GIP activation can further support fat metabolism when estrogen levels drop. Patients with Heart Disease or High Cholesterol The last group of patients I'd like to discuss is patients with heart disease (e.g., heart failure, stroke, heart attack, or even atherosclerosis) or people with high cholesterol. Semaglutide has the strongest cardiovascular outcomes data, reducing major adverse cardiac events by 20% and improving LDL cholesterol (bad cholesterol) and blood pressure. Tirzepatide shows promise for heart and lipid benefits, but those trials are still ongoing. For patients with prior heart attack, stroke, or severe coronary artery disease, semaglutide remains the safest evidence-backed starting point—unless intolerable side effects or weight loss resistance occur. Tolerability Now I want to switch gears a bit and talk about side effects and tolerablity of these peptides. Some patients experience stomach-related side effects like nausea, bloating, or acid reflux on semaglutide. Generally, tirzepatide tends to cause fewer GI side effects, likely due to GIP balancing GLP-1 activity in the gut. So patients struggling with nausea or other stomach-related side effects may find tirzepatide more tolerable. Just something to keep in mind. Individualizing Therapy Lastly, I want to highlight the importance of individualizing weight loss peptide treatments. There's no one-size-fits-all approach when it comes to these therapies. Clinicians should carefully consider a patient's goals, medical history, current medications, and tolerance before choosing the most appropriate option. Setting realistic expectations from the start is essential. It's important to remember that everyone's body responds differently because of factors like hormones, genetics, metabolism, gut microbiome balance, and lifestyle habits. These differences influence how effectively a peptide therapy works and how well it's tolerated. That's why ongoing monitoring and follow-up are such an important part of the process. Providers track progress, adjust dosing when needed, and switch medications if weight loss plateaus or side effects occur. The goal isn't just to lose weight quickly—it's to create a safe, sustainable plan that supports long-term metabolic health and helps patients feel their best. Thanks for listening to The Peptide Podcast.  If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. Until next time, be well, and have a happy, healthy week.

Today we're talking about peptides being researched for addiction. We'll unpack the science behind the incretin system, how those pathways tie into reward and substance use, and focus in on the newest triple‐agonist retatrutide. We'll also look at early evidence for alcohol, tobacco and other substance-use disorders when using certain peptide therapies. If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. https://pepties.com/partners/ What are GLP-1, GIP and the “dual/triple” agonists? First, let's review some biology to ground the discussion. GLP-1 (glucagon‐like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are incretin hormones. Incretins are gut hormones that help with digestion and blood sugar control. They're released by the gut in response to food.  GLP-1 raises insulin levels after you eat to help lower blood sugar, slows gastric emptying, and reduces appetite. It also reduces how much glucagon your body makes. This helps to lower your blood sugar. Medications like semaglutide and dulaglutide work by mimicking GLP-1 and are often referred to as “GLP-1 agonists”. GIP has somewhat overlapping but distinct roles from GLP-1. It too, influences insulin secretion, but it also helps with fat metabolism.  In a nut shell, GIP helps fat cells respond more efficiently to insulin so they release stored fat to be used as energy when your body needs it. This process helps your metabolism shift from just storing energy to burning fat for fuel. Medications like tirzepatide work by mimicking both GLP-1 and GIP and are often referred to as “dual” agonists.  When GIP and GLP-1 are activated together — like in tirzepatide — they work as a team: GLP-1 helps control appetite and slow down digestion. GIP boosts how your body handles insulin and energy. Together, they help reduce hunger, improve metabolism, and burn fat more efficiently. Now here's where it gets a bit tricky.  A newer medication that's still in development, retatrutide, works on three hormone pathways: GLP-1, GIP, and glucagon receptors. It's called a “triple agonist”, and even though it activates the glucagon receptor, it doesn't cause high blood sugar like you might expect. It's about balance. In type 2 diabetes and obesity, the body's hormone signals are out of balance. Retatrutide gently activates the glucagon receptor, but at the same time it strongly activates GLP-1 and GIP receptors — which still help control blood sugar and increase insulin. So blood sugar stays stable or even improves overall. Glucagon doesn't just affect blood sugar — it also increases metabolism and helps the body burn fat and calories. By slightly stimulating glucagon receptors, retatrutide can boost energy use and promote fat loss without causing big spikes in blood sugar. As a result, you get the blood sugar control of GLP-1 and GIP, plus the fat-burning benefits of glucagon activation — leading to even greater weight loss and metabolic improvement.  Right now, retatrutide is in phase 3 clinical trials, which are the final stage of testing before approval. These studies are expected to finish in early 2026, and if results look good, the FDA could approve retatrutide as early as 2027.  Addiction Why is this relevant for addiction? Because the gut-brain axis, reward circuitry, and the pathways that regulate “wanting/consuming” food overlap with those involved in substance use.  Appetite, reward, and craving may share neural substrates (dopamine, GABA, mesolimbic system) and so a drug that reduces drive to eat might also modulate drive to drink, smoke or use other substances. The link between GLP-1/related drugs and substance use disorders  Let's now dive into what the research says about GLP-1 receptor agonists (and related medications) in the context of alcohol, tobacco, and other substances. Let's start with what we know from animal research. In pre-clinical studies, scientists have found that GLP-1 receptor agonists seem to change how animals respond to addictive substances. A systematic review showed that in rodents, treatment with GLP-1 drugs reduced the behavioral effects of alcohol, nicotine, amphetamine, and cocaine. For example, one GLP-1 drug called exendin-4 reduced alcohol-related behaviors in rodents. And even more recently, a study in both male and female rats showed that giving semaglutide, tirzepatide, or even retatrutide, reduced alcohol discrimination, meaning the rats didn't experience the same “feeling” from alcohol as before. This means that the “interoceptive stimulus effects” or the internal sensations — how alcohol feels inside the body, changed. This is really important because this is what often drives people to drink or relapse. So, if these medications can blunt those internal cues, it suggests they might disrupt the rewarding effects of alcohol that help maintain addiction. When we shift to human studies, things get even more interesting. A systemic review found that out of five studies looking at GLP-1 receptor agonists in people with substance use disorders — mostly alcohol and nicotine — three showed real reductions in substance use, while two did not. In one large observational study of over 150 adults with obesity who drank alcohol, those who were taking semaglutide or tirzepatide for at least 30 days reported fewer drinks, fewer binge episodes, and lower overall intake compared to people not on those drugs. A phase 2 clinical trial of once-weekly semaglutide in adults with alcohol use disorder showed similar results — lower alcohol craving and some reductions in drinking behavior. There's also data from a massive registry-based study showing that people with alcohol or opioid use disorder who were prescribed GLP-1 or GIP drugs had 50% lower rates of alcohol intoxication and a 40% lower rate of opioid overdose. Still, experts are cautious — meta-analyses and reviews consistently note that the evidence, while promising, is still early and we don't yet have large, long-term randomized controlled trials. What's Going On? So, what's actually happening inside the brain and body that could explain these changes in craving and reward? How can medications originally made for diabetes and/or weight loss end up helping with addiction?” Mechanistically, GLP-1 drugs may affect the brain's reward system — especially dopamine signaling in areas like the nucleus accumbens — and reduce the “wanting” of reward substances like food or alcohol. They might also calm stress responses and make relapse cues less powerful. And there are probably some physical effects too — things like slower digestion and increased fullness, which might make it harder to physically consume large amounts of alcohol or even smoke as much. But again, many of these findings come from animal models, which don't always perfectly reflect human addiction. Most of the focus so far has been on alcohol, though there's also some early evidence that GLP-1 drugs might influence nicotine use. For substances like opioids or cocaine, the data is thinner and more mixed. Bottom line — at this stage, GLP-1 receptor agonists, and maybe even GIP/GLP-1 dual agonists, represent a really promising new direction for treating addiction — but it's still early days. We also don't yet have human addiction studies on retatrutide, pre-clinical data in rats show that, like semaglutide and tirzepatide, it too, reduces alcohol discrimination. In practical terms, if you're treating patients with obesity or diabetes who also struggle with alcohol or nicotine use, choosing a GLP-1 or dual agonist might offer an unexpected bonus — helping with cravings. It also gives us a new way to talk with patients about how metabolism, reward, and craving are all interconnected. But — and this is important — the data are still limited. Most studies are small, short, and often focus on people with obesity or metabolic disease rather than pure addiction. So, for now, it's an adjunctive idea, not a replacement for established therapies. We'll need larger randomized trials in people with substance use disorders to really understand who benefits, what doses work, and how long the effects last. Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend, please share this episode! Until next time, be well, and as always, have a happy, healthy week.

Hitting a metabolic wall in midlife? You're not alone — and you're not broken. In this episode, Michele Folan, midlife health coach and former diabetes industry insider, breaks down the science (and the truth) behind microdosed GLP-1 and peptide therapy for women 40+.Drawing on many years in diabetes and cardiovascular health, Michele explains how incretin hormones like GLP-1 and GIP regulate appetite, satiety, and insulin sensitivity — and why they've become game-changers for both metabolic and weight health. You'll hear:The wild origin story of GLP-1 (hint: it starts with the Gila monster)Why early GLP-1 drugs revolutionized diabetes careHow microdosing protocols now support fat loss while protecting lean muscleThe real goals: improved A1C, fasting insulin, lipids, inflammation, and energyThis isn't about shortcuts — it's about layering science-backed tools onto strong habits: ✅ Lifting heavy ✅ Eating enough protein ✅ Prioritizing recovery ✅ Partnering with trusted, physician-led telehealth and vetted compounding pharmaciesMichele also dives into other longevity peptides that support sleep, recovery, cognition, skin, and hair health — plus the role of NAD+ in cellular repair and energy.If you've been “doing everything right” and still feel stuck, this episode connects the dots between modern peptide therapy and midlife metabolism — with zero hype and total transparency.

Translink Nordic Tech Stars | #negotiator 356. Interviews with participants of Translink Corporate Finance Nordic Tech Stars event in Helsinki, attended by premier investors and Nordic SaaS and technology companies. The event took place at Savoy restaurant.00:00 Sami Miettinen intro to Translink Nordic Tech Stars00:32 Guests from Paris: Marc Irisson (Translink) & Elie Hodara (InfraVia)01:04 Shout-outs: Lyyti, Vastuu Group, M&M Growth Partners01:41 Interview: Marc Irisson – trends in B2B tech/TMT02:14 Polarized M&A market; deal volumes US vs. Europe02:50 Polarization inside tech: what it means03:15 Flight to quality accelerates since 202303:53 Multiples: 20× EBITDA / ~10× ARR for top assets; others lag04:36 PE dry powder; opportunities for strong-KPI SaaS05:01 Good vintage analogy for investing/exits05:25 Nordic SaaS quality & Rule of 40 call-out05:57 Nordic/Finnish leadership & international scale06:53 Petri Hollmén (Lyyti, Vaaka Partners portfolio)07:33 Hitting the Rule of 40 sustainably07:59 NPS & eNPS stay high while scaling08:25 5M+ ARR club; revenue levels09:01 B2B SaaS positioning; international expansion09:33 Finnish business community & Turku angle10:09 Tero Nummenpää birthday party with Lyyti10:54 Harry Brade (M&M Growth Partners)11:22 AlphaSense: ARR journey & valuation milestone11:54 SiloAI: early stage to breakout12:17 Flexible tickets; strong AI focus12:57 Vertical vs. horizontal AI plays13:33 SaaS multiples: vertical vs. horizontal (market view)14:13 Entry expectations vs. realized outcomes14:32 Spinning off SiloGen (product vs. services)14:57 Compute, LLMs, and infra as value drivers15:25 Niilo Pirttijärvi (Inven)15:54 AI-driven B2B analytics; who it serves16:18 Market/platform analysis use cases16:44 Funding rounds (pre-seed → Series A)17:10 Notable investors such as Tuomo Vuolteenaho17:31 Global ARR mix (US/EU/ROW)17:57 Rule of 700 growth quip18:15 Product investment & scaling18:32 CAC/NRR/churn & profitability lens18:57 AI ecosystem/community notes19:21 B2B SaaS model durability20:02 Growth vs. cash flow; metrics that matter20:32 Gross margin, usage costs, CAC multiples20:55 Building customer success at speed21:11 Founding team split & coding ambitions21:41 Pekka Vanne (Vastuu Group)22:00 Hartwall Capital partnership22:24 ~90% recurring revenue profile22:43 Consulting components at onboarding23:04 Mission: responsibility & ESG enablement23:22 Meaning of Vastuu, culture23:40 International guests & go-to-market24:00 Growth in Finland; expanding offerings24:26 M&A as an internationalization lever24:46 First acquisition done; more considered25:13 Elie Hodara (InfraVia Partners)25:36 Flexible minority/majority; pure B2B software; GIP platform support26:06 Team footprint; value-add (search, cyber, legal)26:35 Sector themes; why Finnish SaaS scales early26:52 Capital-efficient mindset & early structuring27:09 What founders seek (scaling support)27:25 Biz-dev help; Scandinavia & Europe27:44 Depth across Finland (not just Helsinki)28:33 Rule of 40: useful proxy, not a hard screen29:07 Tracking over hold; context matters29:49 Translink Corporate Finance in tech space30:20 Contact www translinkcf dot com or fi30:52 Subscribe to Translink SaaS Valuation QuarterlyWatch all Insider episodes and support Samihttps://www.youtube.com/channel/UCRI34L9OtDJuZpaWicbNXzg/join#neuvottelija #negotiator Sami Miettinen

Can medications like Ozempic and Mounjaro actually do more than help you lose weight? This minisode features highlights from our full conversation, which premiered October 7th, 2025. Watch the full episode here → https://youtu.be/AcVIiy201H4?si=nlaFL3JnoZHxQVFh Dr. Rocio Salas-Whalen and I explore the difference between GLP-1, GIP, and triple-agonist drugs — and what's next in obesity medicine, how estrogen changes after 40 drive midsection weight gain and inflammation, why GLP-1s reduce cancer and Alzheimer's risk through anti-inflammatory and neuroprotective effects and how obesity and insulin resistance impact fertility and PCOS — and how GLP-1s can help.If you've ever wondered whether GLP-1s are just “weight loss shots” or a real step forward in metabolic and brain health — this “minisode” is a must-listen. *** Follow Dr. Salas-Whalen: Instagram: @drsalaswhalen TikTok: @drsalaswhalen @strengthmd @thedryrevolution *** I'm Louisa Nicola — clinical neuroscientist — Alzheimer's prevention specialist — founder of Neuro Athletics. My mission is to translate cutting-edge neuroscience into actionable strategies for cognitive longevity, peak performance, and brain disease prevention. If you're committed to optimizing your brain — reducing Alzheimer's risk — and staying mentally sharp for life, you're in the right place. Stay sharp. Stay informed. Join thousands who subscribe to the Neuro Athletics Newsletter → https://bit.ly/3ewI5P0 Instagram: https://www.instagram.com/louisanicola_/ Twitter : https://twitter.com/louisanicola_ Topics discussed: 00:00 – Intro 00:04  – The Probiotic GLP-1 Myth 00:19 – The “iPhone Evolution” of GLP-1 Drugs 00:52 – GLP-1 vs GIP vs Triple Agonists Explained 01:24 – Phase 3 Results & Massive Weight Loss Outcomes 01:38 – The Role of Glucagon in Weight Loss 01:56 – Menopause, Estrogen & Midlife Weight Gain0 3:06 – The “Fat Shift” After 40 04:01 – Can You Combine HRT and GLP-1s? 06:17 – “Willpower” vs Biology in Obesity 07:49 – The Genetic and Hereditary Roots of Obesity 08:57 – Breaking the Transgenerational Cycle 09:30 – Thyroid Cancer Myths and GLP-1 Safety 10:49 – GLP-1s and Breast Cancer Prevention 12:06 – Inflammation as the Root of Disease 12:28 – Neuroprotection and Alzheimer's Prevention 13:17 – GLP-1s, PCOS & Fertility Benefits 13:53 – The Positive Ripple Effect on Mental Health 14:21 – GLP-1s Reduce Alzheimer's Risk by 33% 14:58 – The Future of Metabolic Health Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Let's dive into the latest news shaping this dynamic industry.Bristol Myers Squibb recently made headlines with their acquisition of Orbital Therapeutics for a remarkable $1.5 billion. This strategic move is aimed at enhancing their in vivo cell therapy capabilities, particularly in treating autoimmune disorders. In vivo cell therapy is a pioneering approach that allows genetic modifications directly within a patient's body, potentially revolutionizing the treatment landscape for numerous conditions. This acquisition underscores Bristol Myers Squibb's commitment to pushing the boundaries of innovative cell therapy technologies and reflects a broader trend in the industry towards personalized medicine.In another significant development, AstraZeneca has aligned with the Trump administration's Most Favored Nation pricing program, agreeing to provide Medicaid drugs at prices competitive on a global scale. This decision marks a strategic shift towards cost reduction, especially in chronic disease management and respiratory therapeutics. The move is indicative of AstraZeneca's efforts to adapt to regulatory pressures and evolving policies that emphasize value-based healthcare delivery.Meanwhile, Ypsomed has announced plans to invest $248 million in establishing a manufacturing facility in North Carolina. This facility will focus on producing auto-injectors, essential for treating diabetes and metabolic disorders. The investment signifies a strategic operational expansion aimed at meeting rising demand in North America, highlighting the growing importance of drug delivery devices in the therapeutic landscape.Turning to clinical trials, Regeneron has unveiled promising Phase 1/2 data for its DB-OTO gene therapy targeting genetic hearing loss in children. By using AAV vectors to address DFNB9-related synaptic transmission deficits, this therapy could mark a breakthrough for those suffering from hereditary hearing conditions. Satellos has also presented encouraging Phase 1 results for SAT-3247, an oral small molecule targeting AAK1 in Duchenne muscular dystrophy, with plans to proceed to Phase 2 trials focused on muscle regeneration.In oncology, Taiho and Cullinan's Phase 2 data on zipalertinib showed efficacy against EGFR-mutated non-small cell lung cancer with brain metastases. This advancement highlights the potential of tyrosine kinase inhibitors in precision oncology. Similarly, Arcus Biosciences reported a median survival of 26.7 months for its combination therapy with domvanalimab and zimberelimab in gastroesophageal adenocarcinoma trials, underscoring the promise of TIGIT-targeted therapies.Assembly Biosciences has shared promising Phase 1b results for its ABI-5366 helicase-primase inhibitor, achieving an impressive 94% reduction in herpes simplex virus shedding. OS Therapies reported significant survival improvement with its OST-HER2 vaccine in recurrent pulmonary metastatic osteosarcoma patients, positioning HER2-targeting immunotherapies as promising cancer treatment interventions.Cabaletta Bio has made strides with its resecabtagene autoleucel CAR-T therapy, demonstrating B cell elimination without preconditioning in pemphigus vulgaris trials. This innovation opens new doors for autoimmune disease management through advanced cell therapies.On the business development front, Roche's out-licensing of its GLP-1/GIP agonist CT-388 to Chugai for diabetes and obesity treatment exemplifies strategic partnerships focused on addressing metabolic disorders through novel small molecules.The sector is also witnessing significant financial activities with Evommune filing an IPO to advance treatments for inflammatory conditions. Meanwhile, Quoin Pharmaceuticals raised $104.5 million through private placement to concentrate on rare disSupport the show

Are you doing all the right things — eating well, balancing your hormones, supporting your gut, getting your steps in — but the scale still isn't budging?You're not crazy. You're not lazy. And you're definitely not alone.In this episode of The Period Whisperer Podcast, I'm diving into one of the most talked-about — and misunderstood — tools in midlife health: peptide therapy. Specifically, we're talking about GLP-1s and GLP-1/GIP + B12 blends, and how microdosing these peptides can help support your metabolism, energy, and weight loss without extreme diets or overexercising.I'll walk you through: ✨ What GLP-1 and GIP peptides actually are — and how they work with your body (not against it) ✨ The difference between traditional GLP-1s and the microdose GLP-1/GIP + B12 stack ✨ Why it's not cheating to get help supporting your metabolism in perimenopause ✨ The real reasons women get “stuck” with their weight in midlife — and how peptides can help rebalance blood sugar, reduce inflammation, and calm “food noise” ✨ Why microdosing is my preferred approach (plus the incredible results I've seen in my clients and my wife!) ✨ The foundational lab markers to check before starting any peptide protocolIf you've been feeling stuck — even though you're doing everything right — this episode will help you see why it's not your fault, and how science-backed peptide therapy might be the missing piece to help your body respond again.

W tym odcinku rozmawiamy z dr. Tadeuszem Oleszczukiem o tym, czym dziś jest mądre zdrowie: od kuchni i snu, przez mikrobiotę i hormony, po realia systemu ochrony zdrowia. Pytamy o dwa posiłki dziennie, cukier i żywność ultraprzetworzoną (UPF), czy „prawdziwy chleb” jeszcze istnieje i czym różni się rzemiosło od przemysłu (biopiekarz). Dyskutujemy o „jedzeniu jako lekarstwie”, wpływie nowych technologii na sen i apetyt, o zmianach jakości żywności i ich możliwym związku z płodnością oraz zdrowiem dzieci. Wchodzimy też w farmakoterapię: kiedy styl życia nie wystarcza, a kiedy warto rozważyć GLP‑1/GIP (np. Ozempic/Wegovy, tirzepatyd) — i jak łączyć leki z nawykami, by uniknąć nawrotów. Na koniec: jak żyć z dala od apteki, jakich leków OTC nadużywamy i jak rozsądnie korzystać z medycyny.

SUPPORT OUR WORK: OTPLinks.com

Recorded live at Leverage Fitness, so please excuse the background noise.                        Hear what we have to say about: Longevity - Lifespan vs Healthspan Taking a look inside - why getting more extensive bloodwork is vital Weight Loss simplified - calories in vs calories out Medications, Prescriptions and Dietary Aids - deciding which might be best for you Nutrtion - do you have to eat healthy to be healthy? Supplements - which are the most important to consider? Sleep - how does it affect weight, energy and recovery? Taking control when feeling overwhelmed  Gym myths     APEX RX https://apexrx.net   Jesse Frank https://www.lvrgfit.com jesse.dfrank@gmail.com   Charlie Seltzer https://drseltzerlifestylemedicine.com info@drseltzerweightloss.com

Willkommen im Herbst, liebe Leute, und willkommen zu einem neuen EvidenzUpdate. Vorsicht, heute kommt es ganz dicke. Wir nehmen uns eine aus mehreren Gründen interessante Arbeit vor: einen Head-to-Head-Vergleich, der die GLP-1-Analoga Semaglutid und Tirzepatid (das als Twinkretin auch an GIP bindet) untersucht bei Menschen mit kardiometabolischer Herzinsuffizienz (konkret HFpEF).

Welcome to The Peptide Podcast. In this episode, we're unpacking the latest on retatrutide and how it measures up against semaglutide and tirzepatide.  If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  https://pepties.com/partners/ We'll look closely at what the studies tell us so far — from overall weight loss to reductions in visceral fat and how much lean muscle mass is preserved. We'll also talk about where the evidence is solid, where it's still developing, and why cross-trial comparisons should be made with caution. What is retatrutide? So let's start with the basics—what is retatrutide? Retatrutide is a new type of weight-loss medication called a triple agonist. That sounds fancy, but what it really means is that it targets three hormone receptors in the gut and pancreas: GLP-1, GIP, and glucagon. Each of these plays a slightly different role in metabolism and appetite regulation. To break it down: GLP-1, which you might already know from drugs like semaglutide, mainly slows digestion, helps you feel full, and improves insulin sensitivity. GIP, which tirzepatide targets along with GLP-1, also helps regulate blood sugar and may improve how the body stores and burns fat. Retatrutide adds glucagon receptor activation on top of that, which seems to further boost fat burning. So how does this compare to semaglutide and tirzepatide? Semaglutide is a GLP-1-only drug, so it mainly works by reducing appetite and slowing gastric emptying. Tirzepatide is a dual agonist, hitting GLP-1 and GIP, which gives it a slightly stronger effect on blood sugar control and fat metabolism compared to semaglutide. Retatrutide goes one step further by adding glucagon activity, potentially giving more total fat loss. In other words, you can think of it like a spectrum: semaglutide hits one target, tirzepatide hits two, and retatrutide hits three—each additional receptor seems to enhance metabolic effects and fat loss in clinical trials. That's why people are excited about retatrutide, though it's still early, and we're waiting on larger studies to see exactly how it compares head-to-head with the others. And that's going to be key, since right now we don't have direct comparisons to other advanced therapies like semaglutide or tirzepatide in the published Phase 2 data. How does retatrutide compare to semaglutide and tirzepatide? Total body weight loss: Now let's put these three medications side by side and look at what the trials actually tell us about total body weight loss. Starting with retatrutide: in its Phase 2 obesity program, the numbers were unusually large, especially given the relatively short trial window. In the 48-week study, people on the higher doses—8 or 12 milligrams weekly—lost about 22 to 24% of their body weight on average. That's the result that really made headlines. It's worth noting that some trials report slightly different averages depending on the group studied—people with obesity but no diabetes versus people with type 2 diabetes—but across the board, that 48-week signal is consistently very strong. For comparison, let's step back to semaglutide at the 2.4 mg dose, which was tested in the pivotal STEP-1 trial. Over 68 weeks, participants lost about 15% of their body weight on average. That was a landmark finding when it was published in the New England Journal of Medicine—it essentially set the modern benchmark for what a GLP-1 monotherapy could do. Then we have tirzepatide, the dual GIP and GLP-1 agonist. The SURMOUNT-1 trial, which ran for 72 weeks, showed dose-dependent results: about 15% weight loss at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, compared to only around 3% with placebo. Other obesity studies with tirzepatide have backed this up, especially at the higher doses. And in head-to-head comparisons with semaglutide, tirzepatide has consistently come out on top. So if we zoom out: retatrutide's Phase 2 data suggest the greatest average reductions—over 22%—in less than a year. Tirzepatide follows closely behind with around 21% over 72 weeks. And semaglutide shows very meaningful, but smaller, weight loss of around 15% over a similar time frame. The big caveat here is that these aren't perfect apples-to-apples comparisons. The trials differed in their length, the types of patients enrolled—some had type 2 diabetes, some did not—their baseline weights, and even the way results were reported. Plus, retatrutide is still in Phase 2 for obesity, whereas semaglutide and tirzepatide already have large Phase 3 programs and real-world data backing them up. Visceral fat reduction: Next, let's talk about visceral fat reduction—that's the deep fat that surrounds organs like the liver, pancreas, and intestines. It's particularly important because high levels of visceral fat are strongly linked to cardiometabolic disease. Starting with retatrutide, one of the Phase 2 substudies used DEXA scans to measure body composition in detail. At the higher doses—8 and 12 milligrams per week—participants saw visceral fat drop by about 29 to 31% over 48 weeks. That's a very large relative reduction in under a year and one of the reasons people are excited about retatrutide's potential not just for weight loss, but also for improving long-term metabolic health. How does that compare to the other drugs? With semaglutide, we also have DEXA and imaging substudies from the STEP program and follow-up mechanistic work. These consistently show meaningful visceral fat reductions, along with improvements in the ratio of lean to fat mass. The difference is that semaglutide studies typically report VAT changes as “significant and clinically relevant,” but they don't always publish one clear headline number that's directly comparable to retatrutide's ~30%. In other words, semaglutide definitely lowers visceral fat, but depending on the study and population, the exact percentage looks different. For tirzepatide, we also have imaging-based data from the SURMOUNT trials and related body-composition studies. These show that the majority of weight lost is fat mass—including a significant portion of visceral fat. Some analyses report reductions on par with what's seen with GLP-1 therapies, while others suggest tirzepatide may push a bit further. But again, the actual percentages vary depending on whether the study used DEXA, CT, or MRI, and on who was enrolled. The big caveat here is that we don't yet have a head-to-head imaging study comparing all three drugs in the same population with the same methods. Retatrutide's ~30% visceral fat drop is certainly eye-catching, but without that kind of standardized comparison, it's hard to say definitively whether it's truly better than semaglutide or tirzepatide. Lean muscle mass preservation: Now let's shift to lean mass preservation, which is just as important as total weight or fat loss. Across all of the modern obesity drug trials, one thing has been consistent: most of the weight people lose is fat, but some lean tissue is lost too. That's expected whenever you're in a sustained calorie deficit. The question is how much muscle is preserved, and how the proportions break down. With retatrutide, the DEXA substudy showed something reassuring. Even though people lost a lot of total weight and fat, the proportion of lean mass lost compared to total weight loss was similar to what we see with other therapies. In other words, the drug seems to drive large fat reductions without causing disproportionate muscle loss. Interestingly, the absolute amount of lean tissue lost in kilograms was pretty stable across different doses, even though fat loss varied quite a bit. That suggests the extra weight loss with higher doses is really coming from fat, not muscle. Looking at semaglutide, the STEP trials with DEXA scans reported the same general pattern. People lost more fat than lean mass, and when you adjust for the total weight loss, body composition actually improved. In fact, some analyses showed a slight increase in the percentage of body weight that was lean tissue, even though the absolute lean mass in kilograms went down. So again, it's not that muscle isn't affected—it is—but fat loss makes up the majority of the change. For tirzepatide, the SURMOUNT body-composition studies found that about 75% of the weight lost is fat and about 25% is lean mass. That split is very similar to what was seen in the placebo groups, which means the drug isn't shifting the balance unfavorably. It preferentially reduces fat, while lean mass preservation is in the same ballpark as semaglutide and retatrutide. Now, here's the important nuance: lean mass on a DEXA scan isn't just skeletal muscle. It includes water, organ tissue, and other components. So if someone loses 3 or 4 kilograms of “lean mass,” we don't know how much of that is functional muscle versus water or smaller organ size. That's why these numbers can be misleading if you take them at face value. And this is where lifestyle comes in. Resistance training and adequate protein intake are critical alongside medication. Lifting weights or doing bodyweight resistance work helps preserve functional muscle, while getting enough protein—typically somewhere in the range of 0.8 to 1 gram per pound per day depending on age and activity—supports muscle repair and maintenance. Every trial we've seen shows that the best outcomes, in terms of maintaining strength and function, come from pairing these drugs with exercise and nutrition strategies. That way, the unavoidable lean mass changes have far less impact on long-term metabolic health and performance. Limitations, biases, and what's missing (the critical context). No large, peer-reviewed head-to-head trials (yet) comparing retatrutide with semaglutide or tirzepatide for the same endpoints using identical imaging protocols. Most comparisons are cross-trial and therefore imperfect. Retatrutide Phase-2 was often compared to placebo or dulaglutide (in the T2D DEXA substudy) rather than to semaglutide or tirzepatide. A head-to-head (planned/registered) study vs tirzepatide is listed on ClinicalTrials.gov but results are not published yet. Different populations & durations. Some retatrutide data come from cohorts that include people with T2D or NAFLD; semaglutide STEP trials were often in people with obesity (without diabetes) and run longer (68 weeks), while tirzepatide SURMOUNT trials ran to 72 weeks. These differences change the absolute and percent outcomes. Funding and reporting bias. Many of the early retatrutide analyses are industry-funded (Eli Lilly), which is standard for drug development, but it requires us to carefully read methods, endpoints, and completeness of reporting. Independent replication and Phase-3 confirmation matter. Imaging method variation. VAT reported by DXA vs MRI vs CT are not directly interchangeable. Some trials report VAT area, others percent change; that complicates cross-trial percent comparisons.  Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend. Until next time, be well, and as always, have a happy, healthy week.

In this episode of The Health Revival Show, Liz & Becca break down Retatrutide—a new GLP-1, GIP, and glucagon receptor agonist that's making waves in the functional health and metabolic space. Is it really “Ozempic on steroids”? They cut through the hype and bring the context no one's talking about—the importance of muscle preservation, insulin sensitivity, thyroid health, and how to use these tools responsibly (or if at all). Whether you're considering peptides or just curious about this next-gen weight loss compound, this episode delivers the no-BS truth.

In this episode, I share some thoughts on managing hunger.. both when you're in a calorie deficit and in everyday life.We'll talk about what drives hunger (like leptin, ghrelin, and even GLP-1/GIP meds), why it ramps up during dieting, and simple ways to keep it in check through food choices, lifestyle habits, and mindset shifts.If hunger has been making things harder than they need to be, this one's for you.Where to find me:IG: @lukesmithrdCheck out my website HEREFill out a 1:1 coaching application HERE

Sick of trying fad diets that just don't seem to work for you? Find out how to simplify your approach and succeed by learning and applying the principles of weight management.  How to make calories work for you Which proteins are better than others and when to eat protein Preserving lean muscle while losing body fat "Dirty" vs "Clean" diets Including desert and candy during a weight loss journey   APEX RX https://apexrx.net   Jesse Frank https://www.lvrgfit.com jesse.dfrank@gmail.com   Charlie Seltzer https://drseltzerlifestylemedicine.com info@drseltzerweightloss.com

Welcome back to Ozempic Weightloss Unlocked, the show that brings listeners the most current news, research, and perspectives on Ozempic, the medication that has transformed weight loss conversations everywhere.Ozempic, generically known as semaglutide, was originally approved for type two diabetes by the FDA in 2017. Its follow-up, Wegovy, hit the market in 2021 explicitly for chronic weight management. Both drugs belong to a class called glucagon-like peptide-one receptor agonists. These medications work by mimicking a naturally occurring hormone that helps the body regulate blood sugar after meals while also reducing appetite by slowing the digestive process. Many patients taking Ozempic weekly have seen impressive reductions in body weight—up to 16 percent, according to data highlighted by the American Journal of Managed Care.The popularity of Ozempic exploded when its weight loss effects were amplified on social media and through celebrity endorsements. Demand surged, and global interest grew as more people sought medical solutions outside of diet and exercise alone. But Ozempic is not just hype—it's backed by multiple clinical trials and growing medical consensus, though not without debate.Researchers continue to push the boundaries, and major updates are underway. According to Fox News Digital and the Times of India, scientists at Tufts University have developed a next-generation experimental drug aimed at delivering weight loss of up to thirty percent—nearly matching surgical outcomes but without the operation. This new compound works across four hormone pathways: GLP-1, GIP, glucagon, and peptide YY, aiming to deliver robust weight loss with fewer side effects like nausea and muscle loss. The “quadruple-action” drug is still in early preclinical stages, tested only in cells—not yet in humans or animals—but represents a bold step towards more personalized, gentle, and sustainable weight management therapies.For now, single-hormone agents like Ozempic remain widely prescribed. Experts urge those on GLP-1 medications to partner closely with their clinicians, focusing on daily protein, hydration, and resistance training to mitigate risks such as muscle loss and malnutrition. Nutritional support is key, as well as regular follow-ups.Alongside medical progress, litigation and warnings continue to surface. The Lawsuit Information Center reports that thousands of claimants have entered into multidistrict litigation over Ozempic and similar drugs, citing side effects like gastroparesis, or stomach paralysis, and rare forms of vision loss including neovascular age-related macular degeneration and optic neuropathy. A 2025 study out of the University of Toronto found semaglutide users twice as likely to develop macular degeneration compared to others—a small risk, but real and statistically significant. Another concern comes from JAMA Otolaryngology–Head & Neck Surgery, showing a possible increased risk of thyroid cancer among GLP-1 agonist users. The defense argues that many of these side effects are rare, and some findings may be linked to increased medical surveillance, rather than the drug itself. Physicians and patients are encouraged to weigh these risks alongside the benefits and always discuss options thoroughly before starting treatment.As for what comes next, listeners should keep an eye on innovations underway: oral drugs like orforglipron, combination therapies such as CagriSema, and monthly injectables from major firms—all targeting more effective weight loss with easier dosing and fewer downsides. Tirzepatide, branded as Zepbound, is currently considered one of the most potent with trial data showing up to twenty-one percent body weight loss.The obesity epidemic is far from solved, but the next wave of treatments could make weight loss less about suffering and more about smart science. Whether listeners are considering Ozempic, awaiting newer options, or just tuning in for updates, the biggest takeaway is this: work with a trusted healthcare provider, stay informed about the latest findings, and balance medication with healthy lifestyle habits.Thank you for tuning in to Ozempic Weightloss Unlocked. Do not forget to subscribe and share. This has been a Quiet Please production—for more, check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Ozempic continues to dominate news cycles in September 2025, with both scientific developments and celebrity stories capturing headlines. Designed originally for the management of type two diabetes, the medication and others like it are known as GLP-1 receptor agonists, which help regulate blood sugar and can reduce appetite, making them highly effective for weight loss. In the past week, researchers at Tufts University have made waves by unveiling a new experimental “quadruple-action” drug they hope will surpass Ozempic's results. As reported by Fox News and the Times of India, this candidate targets not just the GLP-1 hormone but also GIP, glucagon, and peptide YY, with the goal of matching the 30 percent weight loss typically seen in bariatric surgery, all while minimizing side effects. This is an ambitious aim, given that current drugs often bring unwanted symptoms such as nausea, muscle loss, and weight regain. However, the new drug has only been tested in cell cultures so far and will need years of animal and human trials before it becomes widely available.Ozempic itself remains widely prescribed for people with obesity and continues to be in the spotlight due to reports of its effectiveness paired with manageable side effects when overseen by experienced physicians. Still, the risks of muscle loss and malnutrition require users to balance medication with a disciplined regimen of nutrition and resistance training. The cultural conversation about Ozempic, however, has recently shifted from strictly medical debates to the realm of celebrity influence, especially as Oprah Winfrey's transformative journey with the drug has been in the headlines nearly every day this week.Oprah, known for her openness about her decades-long struggle with weight, took center stage at Ralph Lauren's New York Fashion Week show just days ago, making headlines for her dramatic weight loss. According to Media Take Out and Radar Online, Oprah was seen in a fitted and chic ensemble that highlighted what insiders claim is a forty pound reduction, bringing her to a size four, her smallest size since the nineteen eighties. Paparazzi photos were widely circulated, and feedback was immediate and intense, with some admirers celebrating her healthy, radiant appearance and others fueling speculation about her use of Ozempic or related medications. While Oprah herself admitted publicly last year to using Ozempic, describing the medication as “a gift, not something to hide behind” and framing it as a means of managing lifelong struggles, she has not given detailed comment in the last seven days. Her most recent Instagram posts, promoting her latest book club selection, prompted such a strong response that she turned off the comments, signaling just how sensitive and intense the public reaction has been.The broader Ozempic conversation in the last week has also included updates on ongoing litigation in the United States, as courts and lawyers debate whether Novo Nordisk, the drug's manufacturer, adequately warned users of risks such as gastroparesis and vision problems. As reported by the Lawsuit Information Center, over two thousand lawsuits have been consolidated in federal courts, focusing on both gastrointestinal symptoms and rare cases of vision loss that some users attribute to the medication. While most users experience positive results, the growing number of legal claims highlights the demand for more transparent labeling and comprehensive risk evaluation.Despite these issues, medical professionals continue to recommend GLP-1 drugs like Ozempic for patients who struggle with obesity and for whom other approaches have failed, emphasizing the need for individualized care. Doctors urge patients to pair medications with sufficient protein intake, hydration, strength training, and quality sleep to prevent muscle and bone loss. The Tufts University innovation, still in early stages, reflects a drive toward safer, more personalized treatments that may eventually sidestep the most common drawbacks of current medications.For listeners who follow celebrity news, Oprah Winfrey's story remains one of the most visible testaments to the power and controversy of Ozempic. Her experience—now widely discussed and often scrutinized—demonstrates how medical advances can intersect with cultural norms, personal empowerment, and public debate. In the words Oprah shared during her journey, the availability of credible, medically approved options can bring relief and a fresh sense of hope to people who have lived with stigma for much of their lives.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

In this emotional Flashback Friday episode of The Radio Vagabond, I travel to Bessemer, Alabama to experience Gip's Place  –  a legendary juke joint founded in the backyard of Henry “Gip” Gipson. At the time, Gip was an astonishing 97 years old, still hosting Saturday night blues sessions in his tin-roofed music shed alongside family, locals, and wandering musicians. His motto, “No black, no white, just blues,” resonated through every note. Update: Sadly, Henry “Gip” Gipson passed away on October 8, 2019, at the age of 99, closing a chapter on one of America's last authentic juke joints. See pictures and read more on https://www.theradiovagabond.com/066-alabama/ This Flashback Friday episode was first released on March 15, 2019.

In this emotional Flashback Friday episode of The Radio Vagabond, I travel to Bessemer, Alabama to experience Gip's Place  –  a legendary juke joint founded in the backyard of Henry “Gip” Gipson. At the time, Gip was an astonishing 97 years old, still hosting Saturday night blues sessions in his tin-roofed music shed alongside family, locals, and wandering musicians. His motto, “No black, no white, just blues,” resonated through every note. Update: Sadly, Henry “Gip” Gipson passed away on October 8, 2019, at the age of 99, closing a chapter on one of America's last authentic juke joints. See pictures and read more on https://www.theradiovagabond.com/066-alabama/ This Flashback Friday episode was first released on March 15, 2019.

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he dives into today's top stories shaping America and the world. In this episode of The Wright Report, we cover the shocking assassination of Charlie Kirk, Russian drones breaching NATO airspace, Trump's war on Venezuela's cartels, Mexico's tariff fight with China, a pharmaceutical victory in Tennessee, and new revelations in the 9/11 families' lawsuit against Saudi Arabia. From political violence at home to dangerous escalations abroad, today's brief carries heavy news on a day of prayer and remembrance.   Charlie Kirk Assassinated in Utah: The 31-year-old Turning Point USA founder was gunned down while speaking at Utah Valley University. President Trump called him “a martyr for truth and freedom” and ordered flags at half-staff. Video shows a sniper shot to the neck from a rooftop as Kirk addressed thousands of students. MSNBC sparked outrage with coverage that suggested Kirk's “awful words” made his death inevitable. Bryan warns, “The seal has now been broken: if you make those arguments or say those words, you're fair game too.”   Russian Drones Violate Polish Airspace: NATO confirms 19 Russian drones flew over 150 miles into Poland, with several shot down by Dutch and Polish jets. Bryan cautions that even an accident could spark a “Gulf of Tonkin–like incident” dragging NATO into direct war with Moscow.   Trump Escalates War on Venezuela's Cartels: After U.S. forces sank a drug boat killing 11, critics accuse Trump of overstepping presidential authority. War Secretary Pete Hegseth countered: “This strike sent a clear message: If you traffic drugs toward our shores, the United States military will stop you cold.”   Mexico Tariffs Chinese Imports: President Claudia Sheinbaum hikes tariffs on Chinese cars and textiles to 50 percent, aiming to shield Mexican workers and appease Trump's demands to close tariff loopholes. Bryan notes this could undercut Beijing's backdoor into U.S. markets.   Saving U.S. Antibiotics in Tennessee: Trump brokers a deal forcing Walmart and McKesson to buy amoxicillin from Bristol, Tennessee, rescuing America's last antibiotic factory from collapse. “Don't bet against America,” Bryan says, “because with leadership that actually loves this country, we will win.”   9/11 Families' Lawsuit Against Saudi Arabia Advances: A New York judge allows families to pursue claims that Saudi intel officers Omar al-Bayoumi and Fahad al-Thumairy aided hijackers. ProPublica reports al-Bayoumi was a Saudi intel asset in the U.S. coordinating with the GIP. Bryan calls for Trump to declassify CIA files: “It's time for some sunlight on what did or didn't happen that horrific day.”   "And you shall know the truth, and the truth shall make you free." - John 8:32     Take your personal data back with Incogni! Get 60% off an annual plan at incogni.com/TWR and use code TWR at checkout.     Keywords: Charlie Kirk assassination Utah, Trump martyr for truth, MSNBC Charlie Kirk coverage, Russian drones Poland NATO, Trump Venezuela drug cartels strike, Pete Hegseth drug cartels al Qaeda, Mexico tariffs Chinese imports Sheinbaum, Trump tariff war China backdoor, U.S. antibiotics Bristol Tennessee amoxicillin, Walmart McKesson Trump drug deal, 9/11 families lawsuit Saudi Arabia, Omar al-Bayoumi Saudi intel, Fahad al-Thumairy Saudi cleric, CIA Saudi 9/11 declassification

Ozempic continues to lead weight loss headlines this week, as researchers and public figures weigh in on its cultural significance, effectiveness, risks, and the next generation of weight loss solutions. Recent medical reporting indicates an intensifying push for innovation in pharmaceutical weight management. At Tufts University, scientists have crafted a new experimental drug that aspires to surpass Ozempic by targeting four distinct hormones—GLP-1, GIP, glucagon, and peptide YY—rather than just GLP-1 or GIP. This novel approach aims not only for a greater degree of weight loss, with laboratory targets up to thirty percent, but also promises to mitigate the unpleasant side effects often experienced with existing drugs like Ozempic and Wegovy. If successful, the results would rival those of bariatric surgery without surgical intervention. The new compound is engineered for broader metabolic impact, supporting appetite control, minimizing nausea, balancing energy, and optimizing fat burning. However, the medication is still in early development, with laboratory and animal trials ahead before any human use or clinical rollout. Researchers and doctors alike continue to emphasize that while single-agent GLP-1 drugs such as Ozempic are currently effective for most patients, they can cause notable muscle loss and malnutrition if not managed with proper nutrition and strength training. There is ongoing conversation among health professionals about combining these medicines with healthy lifestyle practices in order to minimize risks and sustain benefits.Ozempic's cultural relevance has also been amplified by celebrities, none more so than Oprah Winfrey, who continues to be a focal point in discussions about medically assisted weight loss. Within the past week, online platforms have highlighted Oprah's increasingly slim appearance—she herself has attributed the transformation in part to the use of GLP-1 medications following decades of struggle with her weight. On social media and in a recent podcast episode, Oprah reflected on her realization that biology, not just willpower, governs much of one's weight outcomes. She described how GLP-1 medications quiet her mental preoccupation with food in a way that she once thought only belonged to thinner people. For Oprah, naming her medication use was an act of transparency and self-acceptance. She declared she is finished with the stigma and shame often attached to weight loss and pharmaceutical intervention, especially after years of public scrutiny and self-blame. In interviews, she further explained that using Ozempic as a tool—not a sole solution—helped her decouple her sense of self-worth from her body size. Oprah continues to advocate for holistic weight management routines, which include daily movement, mindful eating, adequate sleep, and emotionally supportive practices. Although she is no longer officially involved with Weight Watchers, she maintains that community, accountability, and compassionate health habits remain critical for achieving and sustaining wellness.As Ozempic's popularity has soared, so have concerns and legal disputes. This week, legal updates show ongoing litigation over side effects such as gastroparesis—a condition that slows stomach emptying—while the United States Food and Drug Administration tightens its regulations on raw ingredients for GLP-1 medications, aiming to prevent the market influx of counterfeit or unsafe drugs. Medical authorities remain cautious, reminding listeners that all medications carry inherent risks, and full transparency around side effects is essential for safe prescribing.Additionally, new scientific research out of Australia this week raised red flags about women of reproductive age using GLP-1 receptor agonists like Ozempic for weight loss without considering reproductive health consequences. Many young women starting these medications do not use effective contraception, despite well-documented risks to pregnancy outcomes, highlighting the need for better clinical counseling as uptake continues to surge.In sum, the past week reveals a turning point for both Ozempic and the broader landscape of medical weight loss. The next generation of treatments is taking shape in the lab, even as current drugs spark both hope and concern. Public voices like Oprah Winfrey are helping normalize the use of medical tools while championing compassion and accountability, and ongoing reviews of risks are prompting regulatory reform. As science, culture, and policy evolve side by side, listeners are witnessing a critical shift in attitudes toward health, body image, and the future of weight management.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Per ben quattro volte il GIP di Reggio Calabria respinge le richieste di archiviazione della procura, chiedendo nuove indagini ed esami, dando vita così ad una guerra di perizie tra la procura e la famiglia di Fausto. Strane macchie di sangue, autopsia svolta dopo tre anni dalla morte e un insieme di dettagli che stonano con la ricostruzione suicidaria. La verità sembra a portata di mano ma ogni giorno sembra anche allontanarsi sempre di più mentre la famiglia, a distanza di nove anni, sta ancora lottando in cerca di verità e giustizia per il proprio figlio.See omnystudio.com/listener for privacy information.

Today we're diving into a topic that a lot of people struggle with quietly but don't always feel comfortable talking about: food anxiety. And if you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Maybe you've felt nervous about going to a party because you weren't sure what kind of food would be there. Or maybe you've found yourself planning your entire day around what you'll eat and how to control it. Perhaps you've even finished a meal only to have guilt set in right away. That's what food anxiety looks like—and you are definitely not alone. Today we're going to talk about what food anxiety actually is, why it shows up, what you can do to calm it, and even how some of the newest medications—things like GLP-1s and dual GIP/GLP-1s—may actually help by quieting some of the mental “food noise.” What is food anxiety? At its core, food anxiety is stress or fear around eating. And the thing is, it doesn't look the same for everyone. For one person, it might show up as constantly worrying they'll overeat. For another, it's that lingering guilt after eating something they feel they “shouldn't have.” And sometimes it's more subtle than that—like a constant hum in the background of your mind where you're thinking about food all day, even when you're not hungry. I often describe it like having a radio station in your brain that's tuned into “food talk.” Sometimes it's background noise, sometimes it's blaring, but either way, it's draining. And over time, that stress around eating chips away at both your mental and physical health. Why does food anxiety happen? So why does this happen in the first place? A big part of it is the culture we live in. For decades, we've been bombarded with messages that carbs are bad, fat is bad, sugar is the enemy—and the list keeps changing. That constant labeling of food as “good” or “bad” teaches us to feel guilty when we eat the so-called wrong thing. For others, food anxiety starts when they get a medical diagnosis. If you've been told you have diabetes, heart disease, or that you need to lose weight for health reasons, suddenly every single bite can feel like a math problem. You're not just eating—you're calculating, you're worrying, you're second-guessing. And then there's the way dieting itself messes with our natural signals. When we spend years restricting, counting, and controlling, we often lose touch with our body's hunger and fullness cues. Instead of trusting how we feel, we rely on rigid rules. And when those rules get broken, the anxiety hits hard. And finally, we can't ignore biology. Food, especially highly processed food, lights up reward pathways in the brain. For some people, those signals are incredibly strong—stronger than for others. That means more cravings, more urges, and unfortunately, more guilt when they give in. What can you do about food anxiety behaviorally? Now, here's the good news. There are things you can do to reduce food anxiety, and you don't need to overhaul your entire life to start seeing changes. One of the simplest but most powerful tools is mindful eating. And I know that phrase gets thrown around a lot. But at its heart, mindful eating just means slowing down.  It means actually tasting your food, noticing the textures, and checking in with how your body feels. When you slow down enough to notice satisfaction, you're much more likely to stop eating when you're comfortable instead of stuffed—and that takes a lot of the stress out of the meal. Another shift that helps tremendously is dropping the “good” and “bad” food labels. Health isn't decided by one cookie, just like it isn't guaranteed by one salad. What matters is your overall pattern, week by week, month by month. When you start to see food as neutral—as fuel, as enjoyment, as part of life—it loosens the grip of guilt and allows you to be more flexible. And speaking of flexibility, having a loose structure around meals can be calming. Instead of rigid dieting rules, like “I can never eat after 7 p.m.,” focus on balance. A meal that has some protein, some fiber, and a little healthy fat is naturally stabilizing. It helps keep blood sugar steady, which means fewer spikes and fewer crashes. And when your body feels stable, your brain feels calmer, too. It's also worth paying attention to your personal triggers. For some people, weekly weigh-ins, keeping a food log, or using a nutrition app can be helpful. But for others, they actually fuel the anxiety. If you notice those things making you more stressed rather than less, it's okay to step away from them. You can still eat intentionally without logging every single bite. And while we are on the subject of personal triggers like daily or weekly weigh-ins, I want to talk about this a bit more. It's really important to remember, your body weight naturally fluctuates from day to day. Daily weight changes are completely normal and can happen for a bunch of reasons.  Your body might hold onto water from salty foods, hormones, or just changes in hydration. What you've eaten recently can also temporarily add weight, and when you eat carbohydrates, your muscles store them along with water, which can make the scale go up a bit. For women, hormonal changes during the menstrual cycle can cause water retention that shows on the scale as well. On top of all that, if you've been exercising more, you might be building muscle even while losing fat. Because muscle is denser than fat, the scale might not move—or could even go up slightly—while your body is actually getting leaner and stronger. Because of these normal variations, seeing a slightly higher number on the scale one day can feel discouraging—even if you're making great progress. Instead of focusing on daily fluctuations, a better approach is to look at your net overall trend over a month. Tracking the weekly or monthly average gives you a more accurate picture of real progress and helps reduce stress or obsession with the number on the scale And lastly, support makes a big difference. Whether that's working with a dietitian, talking with a therapist, or joining a group, sometimes having someone else in your corner makes it easier to change both your habits and the way you think about food. Where medications may help: GLP-1s and dual GIP/GLP-1s Now let's shift gears for a moment, because in the past few years, there's been an exciting development in how we treat weight and appetite. Medications like GLP-1 receptor agonists—semaglutide is one example—and the newer dual GIP/GLP-1 agonists, like tirzepatide, have been game changers. So what do they actually do? GLP-1s mimic a natural hormone your gut makes after you eat. That hormone tells your brain, “Hey, you're full.” It also slows down how quickly food leaves your stomach and helps keep you fuller, longer. They also cause your pancreas to release insulin when there's too much sugar from food in your bloodstream. This lowers your blood sugar and helps your cells use glucose (sugar from the food you've eaten). This is helpful because extra sugar your cells don't use for energy is stored as fat, which is why high blood sugar can cause weight gain.  The dual GIP/GLP-1s do all of that, plus they act on another hormone called GIP, GIP improves how your body uses sugar AND fat (storing less of both by breaking them down to use for energy). Now, here's where it gets fascinating for food anxiety. People who take these medications often report that the “food noise” in their head finally quiets down. Instead of thinking about food all day, the volume on that radio station turns way down. Meals feel more manageable. A normal portion actually feels satisfying. And for many, that overwhelming urge to snack or binge just isn't there anymore. When your hunger cues are more predictable and less intense, you don't feel like you're constantly fighting your own body. That alone can dramatically reduce the anxiety around eating. And by calming the physical side—the cravings, the urges—it gives you more space to work on the mental and emotional side of eating without feeling like you're swimming upstream. Of course, these medications aren't a magic fix. They don't erase years of learned guilt or change the culture we live in. But they can be powerful tools, especially when paired with mindful eating practices and professional support. My Final Thoughts If you take one thing away from this episode, let it be this: food anxiety is real. It's not about weakness or lack of willpower. It's shaped by culture, by biology, by personal history—and it can be incredibly challenging. But there are ways to reduce it. Slowing down and being more mindful at meals, letting go of the “good food versus bad food” mindset, building flexible eating habits, and getting support are all steps in the right direction. And for some, medications like GLP-1s or dual GIP/GLP-1s can make the process easier by quieting the biological noise that drives anxiety in the first place. Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend and please remember you're not alone. Many people struggle with food anxiety, and there is nothing wrong with reaching out for help—whether that's behavioral support, medical treatment, or both. Until next time, be well, and as always, have a happy, healthy week.  

Episode 311 showcases our hosts Dr Jake Sloane & David Segal. In our 'What's trending in Aesthetics?' episodes we discuss popular topics doing the rounds on social media, issues being debated in injector forums or items showcased on the news. We'll cover controversies, big stories and themes that have got injectors and our industry talking. In Chapter 14 our hosts Dr Jake and David explore: the global rise in the use of GLP-1 medications the impact of the 'Trump tariffs' with a huge price hike of Mounjaro (GLP-1/GIP medicine) in the UK - and the implications on the pricing of aesthetic products in the future Kris Jenner's recent facelift and whether not looking your age is the new 'normal' a new on label indication for Botox (platysmal bands of the neck) and why injectors can't afford to ignore this region 00:00 Introduction to Inside Aesthetics 00:47 Welcome to the New Podcast Studio 01:29 Upcoming Conferences and Events 06:26 Exploring GLP-1: The Wonder Drug for Weight Loss 10:28 The Impact of GLP-1 on Aesthetic Practices 21:45 Price Hike in Weight Loss Drugs 23:42 Discussing Botox Price Hike Concerns 24:16 Understanding Gross Margins in Business 24:54 Promoting Our Patreon and Resources 25:17 Price Discrepancies in Pharmaceuticals 26:46 Celebrity Facelifts: The Case of Kris Jenner 28:05 Defining 'Natural' in Cosmetic Surgery 31:25 Combination Treatments for Best Results 37:35 New Trends in Botox Indications 38:36 Improving Consultation Processes 45:10 Concluding Remarks and Contact Information   CLICK HERE TO JOIN OUR PATREON FOR ON DEMAND EDUCATION & SUPPORT CLICK HERE TO BROWSE OUR IA OFFERS FOR DISCOUNTS & SPECIALS CLICK HERE IF YOU'RE A BRAND OR COMPANY & WANT TO WORK WITH US CLICK HERE TO APPLY TO BE A GUEST ON OUR PODCAST JOIN OUR LISTENER WHATSAPP GROUP & SEND US YOUR COMMENTS, SUGGESTIONS OR JUST SAY HI! CONTACT US  

Liver, Lipids, and the Left Ventricle

Voor de seizoensfinale en de 100ste aflevering in Nederland (JA JA MENSEN) blijven we in het Fochteloërveen want de koek is nog lang niet op. Gip heeft nog nooit echt goed een slangenarend gezien dus dat is de doelsoort. Maar ook de wielewaal is weer in het land en het gejodel klinkt al uit de bomen. Het zien is alleen een tweede bij deze vogel. Daarnaast is het lievelingsvogeltje van Arjan ook aanwezig; het paapje. Kortom, het wordt een heerlijke vogeldag vol met verassingen.Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

Get My Book On Amazon: https://a.co/d/avbaV48Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/Download The Bioregulator Cheat Sheet: https://bioregulatorcheatsheet.carrd.co/

We begin Adventure August by bringing you something from the past and we are MANIC! A visit from our very own lost girl had us bangerang as little hair, big teeth Tink gets swole, we consider the origin of bar eggs, lil' Amber Scott's lack of link, a check being a check and a fart being a fart and granny Wendy being a FREAK. Her and Toodles? Girl, no - Girl, yes! Don't be stingy, get dusty for PeterGet yer ship and GIP! It's Hook, this week on Doom Generation! Support this podcast at patreon.com/doomgeneration

Het lijk net een titel van een spannend kinderboek: De Moerasvogels van het Tuschenwater. Een vogel die al lang op het verlanglijstje van Gip staat en gek genoeg óók op die van Arjan, maar dan op de zelf-ontdeklijst. De grote karekiet. Deze vogel lijkt, het zal je niet verbazen, redelijk veel op zijn kleinere broertje, maar dan, hou je vast, groter. Natuurlijk is dit vloeken in de kerk volgens Arjan en heeft hij nog tal van kenmerken die anders zijn als je goed kijkt. Maar oke, voor de beginnende vogelaar kan je rustig beginnen met het feit dat 'ie groter is. Wél een stuk zeldzamer en daar doe je het voor lieve mensen. Althans Arjan dan. ;) Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

This week on Fat Science, Dr. Emily Cooper, Andrea Taylor, and Mark Wright unpack the latest breakthroughs in metabolic medications and why individual biology requires personalized treatment. Dr. Cooper explains how modern therapies for metabolic dysfunction go far beyond the old “one pill fixes all” approach. Discover how hormone-based medications like GLP-1 agonists are changing obesity and diabetes care, why medication response can differ drastically between individuals, and what the future holds for tailored metabolic treatments. You'll come away with a clearer understanding of why effective weight management isn't just about diet or willpower—it's about precision medicine.Key Takeaways:Metabolic dysfunction is a complex, multi-hormonal disease; no single medication will work for everyone.New therapies, including dual and triple hormone agonists (like GLP-1, GIP, and amylin analogs), offer synergistic and individualized effects.Clinical observation shows that increasing doses or the “latest” medication doesn't guarantee better results—some people may even find that their progress disappears after increasing to maximal doses.Lab markers (like ghrelin and leptin) could help personalize treatment, but cost and availability limit widespread testing.Concerns about muscle loss with GLP-1 drugs are common, but clinically, the risk mostly depends on nutrition, strength routines and muscle mass at baseline.Accessibility and cost remain barriers; new small-molecule drugs may improve affordability in the near future.Personal Stories & Practical Advice:Andrea relates how understanding her true metabolic issues, rather than just dieting, led to sustainable health changes.Dr. Cooper describes her clinic's approach to measuring body composition and tracking lean mass to avoid unwanted muscle loss.Listeners are encouraged to work with knowledgeable providers, beware of “one size fits all” narratives, and stay hopeful as newer, more effective treatments emerge.Resources from the episode:Connect with Dr. Emily Cooper on LinkedIn.Connect with Mark Wright on LinkedIn.Connect with Andrea Taylor on Instagram.Fat Science is a podcast on a mission to explain where our fat really comes from and why it won't go and stay away. We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn't a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice.If you have a question for Dr. Cooper, a show idea, feedback, or just want to connect, email us at info@diabesityinstitute.org ordr.c@fatsciencepodcast.com.Fat Science is supported by the non-profit Diabesity Institute which is on a mission to increase access to effective, science-based medical care for those suffering from or at risk for diabesity. https://diabesityresearchfoundation.org/

Vidcast:  https://www.instagram.com/p/DMYbs7tJz7Q/A new so-called “tetra-functional” diet compound has added power and its effects match the weight loss result of bariatric surgery. Chemists at Boston's Tufts University have engineered a next-generation compound that mimics the action of four different gut hormones involved in appetite control, metabolism, and energy use.  They are GLP-1, GIP, glucagon, and the uncommonly mimicked PYY.This novel chimeric peptide could deliver up to 30% body weight loss.  That effect exceeds the effects of our current crop of weight loss drugs semaglutide and tirzepatide, marketed as Ozempic, Wegovy, and Mounjaro.  Semaglutide mimics only GLP1 while tirzepatide mimics both GLP1 and GIP.This compound is newly discovered and not yet ready for clinical application.  When it is, this powerful agent will be an invaluable help for those suffering from excess weight and weight-induced health problems including diabetes, heart disease, and cancer.  The hope is that it will quickly move from the laboratory bench into preclinical and clinical trials…..someday soon.https://www.sciencedaily.com/releases/2025/06/250612081323.htmhttps://pubs.acs.org/doi/10.1021/jacs.5c04095#obesity #semaglutide #tirzepatide #diet #glp1 #gip #glucagon #pyy

Get My Book On Amazon: https://a.co/d/avbaV48Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/Download The Bioregulator Cheat Sheet: https://bioregulatorcheatsheet.carrd.co/

This episode reveals groundbreaking 2025 research that will revolutionize how you approach OMAD (One Meal A Day) fasting. Dr. Scott and Tommy break down a game-changing study showing how your pre-fast meal composition dramatically affects ketosis timing and fat burning efficiency during 24-hour fasts. Discover the shocking difference between starting a fast with a low-carb, high-fat meal versus a high-carb, low-fat meal: the low-carb group reached nutritional ketosis by hour 12, while the high-carb group never achieved ketosis during the entire 24-hour period. Learn how the right pre-fast meal drops insulin by 42% within one hour, increases fat-burning hormone glucagon by 24%, and naturally boosts GLP-1 (the "Ozempic hormone") by 27% and GIP by 34.5% - giving you natural appetite suppression and metabolic enhancement. The hosts explain why this simple meal composition change (60% fat, 30% protein, 10% carbs versus the opposite) can be the difference between plateau frustration and consistent fat loss results. Understand why your dinner OMAD might be sabotaging your progress, how meal timing amplifies these effects, and practical food swaps to optimize your pre-fast nutrition. If you're stuck in the 3-5 pound weight fluctuation cycle despite consistent OMAD fasting, this episode provides the missing piece to unlock sustained ketosis and accelerated fat burning. Essential listening for anyone wanting to maximize their OMAD strategy and achieve consistent, sustainable results without longer fasts or extreme measures. ⁠⁠Take the NEW FASTING PERSONA QUIZ! - The Key to Unlocking Sustainable Weight Loss With Fasting!⁠⁠⁠ Resources and Downloads: ⁠⁠⁠SIGN UP FOR THE DROP OF THE ULTIMATE GUIDE TO BLOOD SUGAR CONTROL⁠⁠⁠ ⁠⁠⁠GRAB THE OPTIMAL RANGES FOR LAB WORK HERE! - NEW RESOURCE! ⁠ ⁠⁠⁠FREE RESOURCE - DOWNLOAD THE NEW BLUEPRINT TO FASTING FOR FAT LOSS!⁠⁠⁠ ⁠⁠⁠SLEEP GUIDE DIRECT DOWNLOAD⁠⁠⁠ ⁠⁠⁠DOWNLOAD THE FASTING TRANSFORMATION JOURNAL HERE!⁠⁠⁠ Partner Links: Get your⁠⁠⁠ FREE BOX OF LMNT⁠⁠⁠ hydration support for the perfect electrolyte balance for your fasting lifestyle with your first purchase⁠⁠⁠ here!⁠⁠⁠ Get ⁠⁠⁠30% off a Keto-Mojo⁠⁠⁠ blood glucose and ketone monitor (discount shown at checkout)! ⁠⁠⁠Click here!⁠⁠⁠ Our Community: Let's continue the conversation. Click the link below to JOIN the ⁠⁠⁠Fasting For Life Community⁠⁠⁠, a group of like-minded, new, and experienced fasters! The first two rules of fasting need not apply! If you enjoy the podcast, please tap the stars below and consider leaving a short review on Apple Podcasts/iTunes. It takes less than 60 seconds, and it helps bring you the best original content each week. We also enjoy reading them! Article Links: https://pmc.ncbi.nlm.nih.gov/articles/PMC11998415/pdf/12986_2025_Article_920.pdf

In this episode of The Common Sense MD, Dr. Tom Rogers dives into the revolutionary practice of microdosing GLP-1 medications, a class of drugs originally developed for diabetes but now widely recognized for their impressive benefits in weight loss, metabolic health, and beyond. Dr. Rogers shares his own experience with microdosing tirzepatide—even though he isn't diabetic or obese—and discusses why these medications are game-changers not just for diabetes and obesity, but for a wide array of health issues.He breaks down how GLP-1 and GIP incretin hormones work, the evolution of these medications, and what makes microdosing effective and accessible for more people. Dr. Rogers also covers the many potential off-label benefits: from cardiovascular and neuroprotective effects, to improved liver function, help with conditions like PCOS and migraines, addiction support, and more. He addresses the cost and accessibility of these drugs, especially through compounding pharmacies, and emphasizes safety, monitoring, and individualized care.Whether you're a patient interested in the latest in metabolic medicine or just curious about GLP-1s, this episode offers a clear, practical, and insightful look at how these medications can fit into a broader strategy for health, longevity, and well-being.What did you think of this episode of the podcast? Let us know by leaving a review!Connect with Performance Medicine!Check out our new online vitamin store:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://performancemedicine.net/shop/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sign up for our weekly newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://performancemedicine.net/doctors-note-sign-up/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@PMedicine⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@PerformancemedicineTN⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Performance Medicine

Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. Today we're diving into a topic that's been everywhere lately: GLP-1 medications like semaglutide and tirzepatide for weight loss. You may know them by names like Wegovy, Ozempic, Mounjaro, or Zepbound. I want to give you a clear, realistic picture of what to expect—because while the media loves to highlight the dramatic before-and-after photos, the real journey can be slower and more nuanced for some. So in this episode, we're going to talk about the truth—what these medications can do, what they can't, how long things really take, and what you need to know to set yourself up for success. Not hype, not magic promises—just real, honest insight to help you understand the process. Let's get into it. How GLP-1 & GIP/GLP-1 Agonists Work So first things first—how do these meds work? Semaglutide is a GLP-1 receptor agonist, and tirzepatide is a dual GIP and GLP-1 receptor agonist. Basically, they mimic natural hormones in your body that help regulate blood sugar, slow digestion, and—most importantly for weight loss—reduce appetite and improve satiety. That means you feel fuller faster and stay full longer. You're not obsessing over food like before. And that's powerful. But—and this is a big one— these peptides don't magically erase years of weight gain overnight. What they do is help make weight loss easier by reducing hunger and supporting your metabolism—but they don't do all the work for you. It's important to remember they're a powerful tool, not a replacement for your efforts. You're still in control of your choices, habits, and long-term success. Why We Titrate the Dose—and What "Therapeutic Dose" Means Now, let's talk about dosing. When you start Wegovy, you don't start at the highest dose. It's gradually increased over several weeks to give your body time to adjust and to help reduce side effects like nausea or stomach upset. The usual schedule looks like this: You'll start with 0.25 mg once a week for the first month. Then it increases every four weeks—0.5 mg, then 1 mg, then 1.7 mg. By week 17, most people reach the full dose of 2.4 mg once a week—that's the dose shown in studies to lead to the most consistent weight loss, with many people losing around 15% of their total body weight over about a year. But here's the thing—not everyone follows this path exactly, and that's okay. Some people need to slow down or stay longer at a lower dose if they're having side effects. Others may need to increase sooner if they're not seeing appetite changes and are tolerating the medication well. And even though 2.4 mg is considered the “therapeutic dose,” not everyone needs to reach it. Some people feel great and lose weight at a lower dose—and if that's you, that's your sweet spot. The real goal is to find the lowest effective dose that controls your hunger, helps you lose weight at a steady pace, and keeps side effects to a minimum. This isn't a one-size-fits-all journey, and pushing through side effects just to hit the max dose isn't necessary—or safe. Your best dose is the one your body handles well and helps you make progress. *How Much Weight Can You Expect to Lose—and How Fast? Let's take a look at the clinical studies. In large trials, people on semaglutide lost about 15% of their total body weight over 68 weeks. For tirzepatide, it was even higher—20% or more in some cases. But here's the thing—those results happened over a year to a year and a half. Not 6 weeks. Not 3 months. It's a marathon, not a sprint. Also, most of the weight loss doesn't happen during the titration phase. You may see some weight loss early on, especially if your appetite plummets. But the bulk of the weight loss happens once you reach and maintain your therapeutic dose. Why Everyone's Journey Looks Different I can't stress this enough—everybody's journey is different. Some people feel zero hunger from their very first injection. Others don't notice a big change until week 10 or 12. Some drop 10 pounds in the first month. Others lose two pounds and feel discouraged. All of those experiences are normal. Your age, hormones, medications, stress levels, sleep, and past diet history? They all play a role. And let's be real—gaining 20, 50, or 100 pounds didn't happen in a few weeks, right? It likely took months or even years of lifestyle habits, hormonal shifts, emotional eating, or underlying conditions. So we have to give ourselves that same grace and patience when we're trying to take the weight off—even with medical support. Navigating Side Effects and Setbacks Let's talk about the side effects. Nausea, constipation, acid reflux, bloating—yeah, these are pretty common as your body adjusts. And sometimes, those symptoms are your body's way of saying: Hey, slow down. Pushing through intense side effects just to hit a higher dose isn't the goal. In fact, it's not safe. You want the lowest effective dose that keeps your appetite under control, the weight coming off gradually, and your side effects minimal or nonexistent. If you need to pause treatment to let your gut settle or even go back down a dose, that's not failure. That's smart, safe self-care. We're in this for the long haul. Trial and Error with Food—and That's OK One part of this journey that catches people off guard is how sensitive your stomach becomes—especially to certain foods or drinks. Greasy or fried foods, spicy meals, carbonated drinks, alcohol—these can all be triggers for nausea or even vomiting while you're on this medication.  And it makes sense when you think about it: the medication slows down how quickly food and drink leave your stomach. So if you're eating or drinking things that already tend to irritate the stomach lining, the effects can hit harder and last longer. Even if those foods didn't bother you before starting treatment, they might now. It's just one of those things your body has to adjust to, and it may take some trial and error to figure out what still works for you. What is Healthy, Sustainable Weight Loss? So what's a healthy pace of weight loss? In general, 1 to 2 pounds per week is considered safe and sustainable. But on GLP-1s, that might vary. Some weeks you may lose 3 pounds. Some weeks, nothing. And guess what? That's normal. You're looking for overall downward trends, not perfection. The goal here is steady, sustainable fat loss—not dropping weight so quickly that you feel miserable, drained, or start losing muscle. Remember, we're not chasing “skinny”—we're aiming for strong, lean, energized, and healthy. And I know we've talked about this before, but it's worth repeating: exercise is not optional when you're on a GLP-1. It's a must. When you lose weight, you lose both fat and muscle. If you're not actively working to maintain or build muscle, you risk becoming weaker and slowing down your metabolism in the process. We want to keep the muscle you have—and ideally, build more—so your body stays strong and your results last. What Is a “Non-Responder”? Now let's touch on something important: what if the medication doesn't seem to work? Let's talk about what it means to be a “non-responder” on a GLP-1 medication like Wegovy or Zepbound. In clinical terms, a non-responder is someone who has been on their therapeutic dose for at least 3 months and has lost less than 5% of their total body weight—even though they're taking the medication correctly and making lifestyle changes like adjusting their diet, increasing physical activity, and managing stress or sleep. Let's break that down with an example: If someone weighs 200 pounds, 5% of their total body weight would be 10 pounds. So if they've been on their therapeutic dose for 12 weeks and have only lost, say, 4 or 5 pounds—despite doing everything right—they may be considered a non-responder. But as we mentioned before, everyone's therapeutic dose may be different. The therapeutic dose isn't just the maximum dose like 2.4 mg of semaglutide or 15 mg of tirzepatide. It's the dose at which you personally begin to experience consistent appetite suppression, weight loss, and minimal side effects. For some people, that may happen at 1 mg of semaglutide. Others may not feel much of a difference until they reach the full 2.4 mg. Some may even respond better at 1.7 mg and not tolerate the higher dose at all. That's why we titrate slowly, monitor your symptoms, and assess both how you feel and how your body is responding. So how do we know if you've reached your therapeutic dose? We look at things like: Has your appetite significantly decreased? Are you noticing earlier fullness or fewer cravings? Are you losing weight consistently over time Are side effects tolerable or nonexistent? If the answer is yes, you're probably at your therapeutic dose. But if the answer is no—if your hunger hasn't changed much, the scale hasn't moved, and you're not noticing any shift in your eating patterns after 3 months on a stable, higher dose—it might be time to re-evaluate. That could mean adjusting the dose, checking for other health issues that might be interfering (like thyroid problems or certain medications), or even considering a different treatment approach. *So what are my final thoughts?  Your journey is unique. Not everyone responds the same way, and that's okay. The key is finding what works for your body, not just what the label says. These medications can absolutely change lives. But they're not magic. They work with your efforts—not instead of them. You'll need to be patient, flexible, and kind to yourself along the way. You may need to tweak your dose, change your food choices, or give your body time to adjust. That's part of the process. And remember—this isn't just about weight loss. It's about reclaiming your health, confidence, and energy. So take it one step at a time. Celebrate every win. And know that slow progress is still progress. Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Until next time, be well, be patient, and keep showing up for yourself. And as always, have a happy, healthy week.

“Obesity Rx

Today's episode dives into Retatrutide—the upcoming “Triple G” weight loss medication creating major buzz. Dr. Lisa shares the science behind this powerful GLP-1 / GIP / glucagon receptor agonist, explains why it's being called the “Taylor Swift of meds,” and answers common questions from a recent women's summer event. From dramatic weight loss results to calming relentless food noise, we explore why Retatrutide may redefine obesity treatment—and why support, not just medication, is key for long-term health, longevity, and weight loss success. Whether you're on a weight loss med, considering one, or just curious, this episode gives you the scoop you'll want before everyone else is talking about it.If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also…We'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you improve your health, live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.

In recent years, the fitness industry has witnessed a notable surge in the utilization of GLP-1 and now also GIP agonists, as a novel approach to enhance weight loss outcomes.In today episode I'm revisiting the topic (I did another episode on GLP-1s in Season 2, you can find that episode HERE) of GLP-1s. I will be discussing:The surprising usage statistics and rapid increase in prevalence of this drug classThe widespread misuse, and over prescription of this drugWhat the use of these drugs says about how society views the obesity epidemicHow GLP-1 impacts motility in the GI tract and those long term consequenceswho might benefit most from these medications, versus who should steer clear My personal thoughts  __________________________________________Join me on the 'gram! Get free recipes and tips delivered right to your inbox every Friday!Learn more about your options for working 1:1 with me: https://www.revivewellness.health/services Schedule a free call with me hereTry Syntrax! To try to the most delicious, gluten free, lactose free "top of the line" whey isolate AND save 25% use the code "syntraxallison" at checkout.Want some FREE LMNT? Use this link for a FREE sample pack with any order!Better Bodies discount code "BB15" at checkout to save 15% on my favorite betterbodies gear! Save 10% on PureFactorFormulations supplements with my code "Revive10" at checkout!

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. It's an exciting time to be practicing in obesity medicine, with groundbreaking tools like Zepbound and Wegovy helping people achieve their weight loss goals in ways that were once unimaginable. Plus, with new medications like retatrutide (the triple agonists) on the horizon, the future of weight management is looking even brighter.But with so many options available, it can be overwhelming to figure out which medication is right for you. How do Zepbound and Wegovy compare? Can you switch between the two? Is one more effective than the other? In this episode, I'll dive into the key differences between Zepbound (Mounjaro) and Wegovy (Ozempic), comparing doses, effectiveness, and answering all your burning questions about how these medications stack up against each other. ReferencesThe Top 5 Mistakes People Make When Starting GLP-1 Season 1 of the Premium Podcast: The Obesity Guide: Behind the CurtainAudio Stamps00:30 - Dr. Rentea sets the stage for a back-to-basics breakdown of Wegovy vs. Zepbound, which touches on key topics like switching, dosing, and access.01:58 - A comparison of Wegovy (GLP-1) and Zepbound (dual GLP-1 and GIP), discussing their average weight loss effects and varying response rates.05:19 - Dr. Rentea discusses the reasons someone might consider switching medications.06:45 - Switching medications shouldn't involve restarting titration, and working with a knowledgeable physician to manage transitions effectively is key.11:45 - Medication can be a helpful tool, but long-term success depends on working with a skilled physician and staying focused on sustainable progress.Quotes“Within the first few months, it's going to become very clear. Do you need an additional tool? Do we need to tweak things? Do we need to change things?”“These are medications, but they're not everything. You still have to do the heavy lifting on the lifestyle aspect behind the scenes. But you have the ability to switch from one to the other.”“You really should be working with someone who is very familiar with these medications, with switching medications, with adding other things to it, with changing things. There is always something else that can be done.”“We do sometimes see higher results with ZepBound, but there's going to be other medication that comes out that's potentially higher than that. At the end of the day, it's what helps me to keep doing all the other things.”All of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com Premium Season 1 of The Obesity Guide: Behind the Curtain -Dive into real clinical scenarios, from my personal medication journey to tackling weight loss plateaus, understanding insulin resistance, and overcoming challenges with GLP-1s. Plus, get a 40+ page guide packed with protein charts, weight loss formulas, and more. April 30/30 registration.